Biogen Inc.'s Form 4 filing
Sangamo Therapeutics, Inc (SGMOQ) · filed Dec 28, 2021
- Accession no.
- 0000875045-21-000060
- Filed
- Dec 28, 2021, 8:11 AM ET
- Trade date
- Dec 23-27, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $699.7K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biogen Inc.CIK 0000875045 | 10% Owner |
| Biogen MA Inc.CIK 0001810387 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2021 | Common Stock | SSaleDisposed | −81,187 | $8.55F1 | −$694,530.43 | 24,155,830 | Indirect | |
| Dec 27, 2021 | Common Stock | SSaleDisposed | −600 | $8.56 | −$5,136 | 24,155,230 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.65, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.